The "Myelofibrosis (MF) - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of the ...

But Seneschal and colleagues were not discouraged overall. The trial "highlighted the efficacy of combining the JAK1/JAK2 inhibitor baricitinib with narrowband UV-B in the treatment of adults with ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

In addition, JAK inhibitors have been approved in multiple diseases including ... JAK3 is a key signal transduction kinase that forms a heterodimer with JAK1, modulates JAK1 phosphorylation of signal ...